Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality
- PMID: 6792913
- DOI: 10.1016/0002-9343(81)90162-5
Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality
Abstract
Fungemias were reviewed in 110 immunocompromised patients hospitalized between November 1, 1974, and December 31, 1977, a Memorial Sloan-Kettering Cancer Center (MSKCC). The incidence of Candida tropicalis fungemia increased each year. Seventy-six percent of the patients with C. tropicalis fungemia and 32.5 percent of those with C. albicans fungemia had either leukemia or lymphoma. Seventy-seven percent of the C. parapsilosis fungemias were related to total parenteral nutrition. Thirty-seven percent of the patients with C. albicans fungemia were receiving oral prophylactic nystatin therapy. The source of fungemia was often difficult to determine: in 60 percent of the patients, only blood cultures were positive for C. tropicalis or Torulopsis glabrata; no cultures were positive for the fungus from any other site before the episode occurred. Serologic tests, including a highly sensitive passive hemagglutination test, showed fourfold increases in titer only inconsistently. A passive hemagglutination-inhibition test for circulating antigen was positive in 50.9 percent of 57 patients with fungemia who were tested and may be a valid indication for treatment. Fungemia usually represented a severe and often fatal disease. The over-all mortality of the 110 patients with fungemia was 79 percent whereas only 23 percent of the patients with C. parapsilosis fungemia died. Among the patients who received more than 200 mg of amphotericin B, 71 percent died despite treatment.
Similar articles
-
Candida tropicalis and Candida albicans fungemia in children with leukemia.Cancer. 1991 Aug 1;68(3):594-9. doi: 10.1002/1097-0142(19910801)68:3<594::aid-cncr2820680325>3.0.co;2-0. Cancer. 1991. PMID: 2065280
-
Candida parapsilosis fungemia in cancer patients--incidence, risk factors and outcome.Neoplasma. 1998;45(5):336-42. Neoplasma. 1998. PMID: 9921924
-
Risk Factors for Candida tropicalis fungemia in patients with cancer.Clin Infect Dis. 2001 Nov 15;33(10):1676-81. doi: 10.1086/323812. Epub 2001 Sep 24. Clin Infect Dis. 2001. PMID: 11568858
-
Candida tropicalis infections in children with leukemia.Leuk Lymphoma. 1993 Jul;10(4-5):369-76. doi: 10.3109/10428199309148562. Leuk Lymphoma. 1993. PMID: 8220136 Review.
-
Nosocomial Candida krusei fungemia in cancer patients: report of 10 cases and review.J Chemother. 1999 Apr;11(2):131-6. doi: 10.1179/joc.1999.11.2.131. J Chemother. 1999. PMID: 10326744 Review.
Cited by
-
Detection of Candida sp. mannan antigen by indirect ELISA-inhibition. In vitro crossed reactivity among mannans obtained from C. albicans A, C. albicans B, and C. tropicalis.Mycopathologia. 1988 Jun;102(3):175-8. doi: 10.1007/BF00437401. Mycopathologia. 1988. PMID: 3050526
-
Candida lung abscesses complicating parenteral nutrition.Thorax. 1988 May;43(5):418-9. doi: 10.1136/thx.43.5.418. Thorax. 1988. PMID: 3143161 Free PMC article. No abstract available.
-
Development of an integrative DNA transformation system for the yeast Candida tropicalis.J Bacteriol. 1990 Aug;172(8):4571-7. doi: 10.1128/jb.172.8.4571-4577.1990. J Bacteriol. 1990. PMID: 2198267 Free PMC article.
-
Risk factors for candidemia in cancer patients: a case-control study.J Clin Microbiol. 1988 Mar;26(3):429-32. doi: 10.1128/jcm.26.3.429-432.1988. J Clin Microbiol. 1988. PMID: 3356785 Free PMC article.
-
Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B.Antimicrob Agents Chemother. 1994 Jul;38(7):1604-7. doi: 10.1128/AAC.38.7.1604. Antimicrob Agents Chemother. 1994. PMID: 7979293 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical